Health Condition 1: null- Type 2 Diabetes Mellitus patients
Conditions
Interventions
Intervention1: Tab Rosuvastatin: Tab Rosuvastatin 20 mg per day given orally once daily for 3 months
Control Intervention1: Not applicable: As we do not have a
comparator agent involved in
the study a
Sponsors
Sri Venkateswara Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Patients with T2DM aged between 30-60 years as per the revised ADA (American Diabetic Association) criteria i.e.,(12) i) Fasting plasma glucose =126mg/dL (7.0 mmol/L) ii) 2 hour plasma glucose =200mg/dL (11.1 mmol/L) iii) Glycosylated hemoglobin (HbA1c) >6.5% (48 mmol/mol)
Exclusion criteria
Exclusion criteria: Patients with other forms of diabetes (T1DM, Gestational diabetes mellitus) Those on insulin therapy Thyroid disorders not on treatment Those on pioglitazone Liver and kidney diseases Other inflammatory diseases Acute illness Malignancy Alcoholics Current smoking Those on cholesterol lowering drugs Individuals who are not willing to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the effect of rosuvastatin on oxidant and antioxidant status in patients with type 2 diabetes mellitus. Timepoint: baseline and after 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Determine the lipid lowering capacity of rosuvastatin by assessment of lipid profile in patients with T2DM before and after 12 weeks of Rosuvastatin treatmentTimepoint: Baseline and after 12 weeks | — |
Countries
India
Contacts
Public ContactAparna R Bitla
Sri Venkataeswara Institute of Medical Sciences
Outcome results
None listed